This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Moderna (MRNA) Seeks Authorization for Booster Dose in Europe
by Zacks Equity Research
Moderna (MRNA) is developing a booster dose of its COVID-19 vaccine, mRNA-1273, for enhancing protection against infection in individuals.
Techne (TECH) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Techne (TECH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
3 Large Biotech Stocks Worth Adding to Your Portfolio
by Zacks Equity Research
REGN, MRNA & VRTX are the three biotech companies that are likely to outperform the sector on the back of strong fundamentals.
Moderna (MRNA) Gives First COVID Jab Booster Data to the FDA
by Zacks Equity Research
Moderna's (MRNA) booster dose of COVID-19 vaccine elicits antibody levels that were much higher than that seen after the two-dose primary schedule.
Moderna (MRNA) Japan Jabs Resume Amid Safety Risk Per Reports
by Zacks Equity Research
Japan allows use of uncontaminated vials from the same lots of Moderna's (MRNA) COVID-19 vaccine that had some contaminated vials, which led to the temporary halt of vaccination in some parts of the country.
Sorrento's (SRNE) COVID Vaccine Effective in Pre-Clinical Study
by Zacks Equity Research
Sorrento (SRNE) announces data from pre-clinical study for its investigational mRNA COVID vaccine. The company also in-licensed rights to highly potent main protease inhibitors against COVID variants.
Pfizer (PFE) Inks Deal With Eurofarma to Make COVID-19 Vaccine
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech ink a collaboration deal with Brazil's Eurofarma for manufacturing and supplying their COVID-19 vaccine, Comirnaty, in Latin America.
5 Bigwigs to Buy on Double-Digit Returns in the Past Month
by Nalak Das
We have narrowed down our search to five U.S. corporate bigwigs that have provided more than 10% returns in the past month. These are: MRNA, REGN, AIG, CARR and NVDA.
Biotech Stock Roundup: REGN, MRNA Offer COVID-19 Updates, TBPH Down on Study Update
by Zacks Equity Research
Regulatory and pipeline updates from Regeneron (REGN) and Moderna (MRNA), among others have been in focus in the biotech industry over the past week.
Has Moderna (MRNA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (MRNA) Outperforming Other Medical Stocks This Year?
Pfizer (PFE), BioNTech Seek Full Approval for COVID Jab Booster
by Zacks Equity Research
The booster dose of Pfizer (PFE)/BioNTech's (BNTX) mRNA-based COVID-19 vaccine, Comirnaty dose induced significant SARS-CoV-2 neutralizing antibody titers in phase III study.
Tap the Red Hot Biotech Sector With These 2 Leveraged ETFs
by Sweta Killa
Investors could easily tap the bullish trend by considering a near-term long on the biotech sector.
J&J (JNJ) Reports Positive Interim Data on COVID Booster Jab
by Zacks Equity Research
The booster dose of J&J's (JNJ) single-shot COVID-19 vaccine achieves rapid and robust increase in spike-binding antibodies in previously vaccinated people with the initial dose.
Moderna (MRNA) Seeks Full FDA Approval for COVID-19 Vaccine
by Zacks Equity Research
Moderna (MRNA) completes rolling submission of BLA to the FDA seeking full approval of its COVID-19 vaccine candidate, mRNA-1273, in the United States.
The Zacks Analyst Blog Highlights: Apple, Regeneron Pharmaceuticals, TJX Companies, Moderna and NVIDIA
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Regeneron Pharmaceuticals, TJX Companies, Moderna and NVIDIA
Nasdaq Tops 15K for First Time: 5 Best Stocks in the ETF
by Sweta Killa
The tech-heavy Nasdaq Composite Index topped 15,000 for the first time ever driven by continued strength in tech stocks.
Vertex (VRTX) Inks New Deal for CRISPR Gene-Editing Rights
by Zacks Equity Research
Vertex (VRTX) collaboration with Arbor will support discovery & development of new treatment options for serious diseases using the latter's CRISPR technology.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Johnson & Johnson and Novavax
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Johnson & Johnson and Novavax
6 Must-Buy Corporate Giants As Major Indexes Hit Record High
by Nalak Das
We have narrowed down our search to six stocks that are members of any of the three major indexes. These are: MRNA, NVDA, TJX, AAPL, DE and REGN.
Nasdaq Crosses 15K for 1st Time Ever; JWN, URBN Beat
by Mark Vickery
On the way to its fourth-straight up day in the market, the tech-heavy Nasdaq wound up surpassing 15K for its first time ever.
3 COVID Vaccine Makers to Watch on Pfizer Jab Full FDA Approval
by Zacks Equity Research
Stocks of coronavirus vaccine makers BNTX and MRNA fly high following complete approval of Pfizer's COVID-19 vaccine. The momentum is likely to continue for these stocks. JNJ is another strong contender in this field.
Pfizer (PFE)/BioNTech Comirnaty Gets FDA's Full Approval
by Zacks Equity Research
Pfizer (PFE)/BioNTech's (BNTX) mRNA-based COVID-19 vaccine, Comirnaty becomes the first vaccine to be granted full approval by the FDA.
Markets Bounce Back as Slow Summer Weeks Are Here
by Mark Vickery
Fewer than 90 companies are scheduled to release earnings this week, and at first glance none look to represent the S&P 500.
Wall Street Waits For The Fed's Big Event
by Zacks Equity Research
Wall Street Waits For The Fed's Big Event.
Valneva (VALN) Begins Submission for COVID-19 Vaccine in UK
by Zacks Equity Research
Valneva (VALN) starts rolling submission for the initial approval of its COVID-19 vaccine candidate, VLA2001, in the United Kingdom.